Author of

• 36050

  +

  P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics (ID 227)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 36072

    +

    P01.16 - Tamoxifen Might Enhance the Effect of EGFR-TKIs on EGFR-Mutant NSCLC Cells (ID 1004)

    00:00 - 00:00  |  Presenting Author(s): Yun-Ting He
    • Abstract
    • Slides

    Introduction
    

    Postmenopausal females with epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC) have longer progression free survival than premenopausal females when they receive EGFR tyrosine kinase inhibitors (TKIs) treatment. The level of estrogen and estrogen receptors (ERs) in lung cancer tissue might affect the response of EGFR-TKIs. This experiment aims to study the expression of ERs in EGFR-mutant NSCLC cell lines and explore the method to improve the efficacy of EGFR-TKIs from the perspective of estrogen.

    Methods
    

    The level of ERs protein in the nucleus, cytoplasm and membrane of EGFR-mutant NSCLC cell lines was evaluated by western blot. The EGFR-mutant NSCLC cell lines were treated with anti-estrogen, EGFR-TKIs, or the combination; the effect of treatment on cells viability was determined by CCK8 arrays.

    Results
    

    Both ERα and ERβ expressed in multiple NSCLC cell lines. The ERα protein in MCF7 cell line was as much as the ERβ protein, but the ERα protein in EGFR-mutant NSCLC cell lines was much less than the ERβ protein. ERβ was detected in nucleus, cytoplasm and membrane of EGFR-mutant NSCLC cell lines. Compared with Tamoxifen or Erlotinib alone, the combination of the two drugs significantly inhibited the viability of PC9 cell line; compared with Tamoxifen or Osimertinib alone, the combination significantly inhibited the viability of H1975 cell line. But Fulvestrant showed little effect on the prohibition of both PC9 cell line and H1975 cell line.

    

    Conclusion
    

    Tamoxifen might improve the efficacy of EGFR-TKIs on EGFR-mutant NSCLC cell lines. Estrogen might interact with EGFR pathway through the ERβ in the cytoplasm and membrane to promote the proliferations of EGFR-mutant NSCLC cells. More information will be shown in the conference.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.